AstraZeneca ( (GB:AZN) ) has issued an update.
AstraZeneca has announced its acquisition of EsoBiotec, a biotechnology company specializing in in vivo cell therapies, for up to $1 billion. This acquisition includes EsoBiotec’s ENaBL platform, which could revolutionize cell therapy by allowing treatments to be delivered in minutes rather than weeks, potentially transforming the patient experience and expanding access to these therapies. The move is expected to enhance AstraZeneca’s cell therapy capabilities and accelerate its ambition to harness the full potential of cell therapies, marking a significant step forward in its oncology and immune-mediated disease treatment strategies.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company based in Cambridge, UK, focusing on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its innovative medicines are sold in more than 125 countries and used by millions of patients worldwide.
YTD Price Performance: 16.25%
Average Trading Volume: 2,817,366
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £186B
See more data about AZN stock on TipRanks’ Stock Analysis page.